Physician profile
Derek H Ohlstein
NPI 1295960946
$4,659.51
in general payments reported to CMS, 2019-2025
31 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $406 · 2021: $706 · 2022: $520 · 2023: $683 · 2024: $442 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $621.14 | 2019-2025 | Hydrus Microstent, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $419.51 | 2019-2023 | Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $395.39 | 2019-2021 | |
| Shire North American Group INC | $337.11 | 2019 | |
| Ocular Therapeutix, INC. | $298.54 | 2021-2024 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $286.79 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $251.96 | 2022-2025 | Envista Envy Iol, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $245.05 | 2020-2023 | |
| Rxsight INC | $220.54 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Abbvie INC. | $212.26 | 2022-2025 | |
| Allergan, INC. | $168.86 | 2019-2022 | |
| Hoffmann-La Roche Limited | $140.40 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $117.55 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $101.64 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $93.59 | 2022-2023 | Rayone Spheric, Omidria, Rayone Aspheric |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $85.74 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $77.59 | 2023 | Syfovre |
| Sight Sciences, INC. | $73.91 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $70.45 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $69.47 | 2019-2021 | |
| Glaukos Corporation | $62.63 | 2020-2024 | Ce-Marked Kxla System |
| Mallinckrodt Hospital Products INC. | $52.48 | 2025 | Acthar |
| Harrow Eye, LLC | $43.48 | 2024-2025 | Vevye, Iheezo |
| Genentech USA, INC. | $40.51 | 2019-2025 | Vabysmo |
| Horizon Therapeutics Plc | $38.55 | 2021-2022 | |
| Eyepoint US, INC. | $32.02 | 2019-2021 | |
| Biotissue Holdings INC. | $24.98 | 2023 | |
| Carl Zeiss Meditec Cataract Technology INC. | $22.06 | 2023 | |
| Eyevance Pharmaceuticals LLC | $20.00 | 2020 | |
| Dompe US, INC. | $18.75 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $16.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Ohlstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.